Advisors Preferred’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Advisors Preferred’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-71,524	Closed	-$6.46M	–	191
2015 Q2	$6.46M	Sell	71,524 -4,438	-6%	-$382K	3.62%	4
2015 Q1	$6.02M	Sell	75,962 -45,134	-37%	-$3.35M	3.18%	4
2014 Q4	$7.6M	Buy	+121,096	New	+$7.11M	3.57%	3
2014 Q3	–	Sell	-30,026	Closed	-$1.39M	–	220
2014 Q2	$1.39M	Buy	+30,026	New	+$1.19M	0.7%	45

Other funds holding BIB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCAM

Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return

WSTAM

Wilbanks Smith & Thomas Asset Management Norfolk, Virginia $3.57B AUM 21.11% 1-Year Est. Return

BHA

Beech Hill Advisors New York $226M AUM 37.59% 1-Year Est. Return

Advisors Preferred's BIB Position: Q3 2015 in Review

Advisors Preferred sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2015, closing a stake of 71,524 shares — an estimated $6.46M sold.

Advisors Preferred first reported a position in BIB in Q2 2014 and held it in 4 quarters. The position peaked at $7.6M in Q4 2014. 24 funds tracked by Wall St. Rank hold BIB as of Q3 2015.

Advisors Preferred reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2015 after selling out during the quarter.
Advisors Preferred sold 71,524 ProShares Ultra NASDAQ Biotechnology shares in Q3 2015, an estimated $6.46M.
Advisors Preferred first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2014 and held it in 4 quarters.
Advisors Preferred's ProShares Ultra NASDAQ Biotechnology position peaked at $7.6M in Q4 2014.
24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2015.

Based on Advisors Preferred's 13F filing for Q3 2015, filed 2 Nov 2015.